Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Adapted from PwC Health Research Institute; Graphic: Axios Visuals

Gene therapies are physically out of reach for many patients, on top of their cost, according to a new PwC Health Research Institute report.

Why it matters: This further exacerbates the rural-urban divide in access to care.

By the numbers: The report looks at 4 treatments approved in the U.S. In 13 states, none of the 4 treatments were available, as of July. And there are only 5 zip codes nationwide in which all 4 are available.

Between the lines: These treatments can be prohibitively expensive even for patients with access to them.

  • The gene therapy Zolgensma is the most expensive drug in the world, with a list price of $2.1 million.
  • There are also affordability questions surrounding CAR-T, as hospitals often aren't fully compensated for the cost of administering it.

What we're watching: There are 30 gene therapies in late-stage testing, per PwC, and the number of clinical trials has grown rapidly over the last decade.

Go deeper: The real drug pricing debate is upon us

Go deeper

Updated 45 mins ago - Politics & Policy

More than a dozen injured in downtown Austin shooting

Police tape in Austin, Texas in 2018. Photo: y Carolyn Van Houten/The Washington Post via Getty Images

A shooting in a busy part of downtown Austin, Texas, early Saturday injured 14 people, including two who are in critical condition.

The state of play: Gunfire erupted around 1:30 a.m. along 6th Street, a popular area with bars and restaurants. The shooting likely began as “some kind of disturbance between two parties,” Joseph Chacon, the interim chief of the Austin Police Department, said at a news briefing on Saturday afternoon.

2 hours ago - Technology

What's Next

Illustration: Sarah Grillo/Axios

Axios What's Next, our new weekday newsletter will be your guide to the waves of change in how we work, play and get around. This Axios AM Deep Dive gives you a taste of what we have in store...

In photos: Harris shows up at Pride parade in downtown D.C.

Vice President Kamala Harris marches in the Capitol Pride Parade on June 12 in Washington, D.C. Photo: Anna Moneymaker/Getty Images

Vice President Kamala Harris dropped in at the Capitol Pride Walk And Rally in Washington, D.C., on Saturday.

The state of play: Harris and second gentleman, Doug Emhoff, joined the crowd, who welcomed them with cheers, according to press reports.